CTKB insider updates holdings after RSU vesting and tax withholding
Rhea-AI Filing Summary
Cytek Biosciences (CTKB) chief technology officer and director reported multiple equity transactions on November 18, 2025 related to previously granted restricted stock units (RSUs). Several RSU tranches were converted into common stock, including blocks of 1,981, 7,363, 5,525 and 6,162 shares, reflecting ongoing vesting of long-term equity awards. To cover tax withholding from these vestings, a total of 4,? (aggregate of 483, 1,793, 1,346 and 1,501) shares were withheld and surrendered to the company at a price of $5.53 per share, rather than being sold on the open market. After these transactions, the insider directly beneficially owned 6,073,327 shares of Cytek common stock. The RSU grants continue to vest over multiple years on specified quarterly and annual dates.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,981 | $0.00 | -- |
| Exercise | Restricted Stock Units | 7,363 | $0.00 | -- |
| Exercise | Restricted Stock Units | 5,525 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,162 | $0.00 | -- |
| Exercise | Common Stock | 1,981 | $0.00 | -- |
| Tax Withholding | Common Stock | 483 | $5.53 | $3K |
| Exercise | Common Stock | 7,363 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,793 | $5.53 | $10K |
| Exercise | Common Stock | 5,525 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,346 | $5.53 | $7K |
| Exercise | Common Stock | 6,162 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,501 | $5.53 | $8K |
Footnotes (1)
- Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
FAQ
What insider transaction did Cytek Biosciences (CTKB) report on this Form 4?
The Form 4 reports that Cytek Biosciences' chief technology officer and director had multiple restricted stock unit (RSU) tranches vest on November 18, 2025, which were settled in shares of common stock with a portion of shares withheld to satisfy tax obligations.
What types of equity awards are involved in this Cytek Biosciences (CTKB) Form 4?
The transactions involve restricted stock units (RSUs), which represent a right to receive one share of Cytek Biosciences common stock per unit. As the RSUs vest, they are settled in common shares according to the specified vesting schedules.
What are the vesting terms of the Cytek Biosciences (CTKB) RSU awards mentioned?
The RSU awards vest over four-year periods with detailed schedules using fractional installments such as 4/48 or 3/48 of the total shares, vesting on quarterly or specific calendar dates including May 18, August 18, November 18, February 18, and March 10 until fully vested.